Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 349
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Nutrients ; 16(7)2024 Mar 28.
Article in English | MEDLINE | ID: mdl-38613030

ABSTRACT

Black tea (BT), the most consumed tea worldwide, can alleviate hyperlipidemia which is a serious threat to human health. However, the quality of summer BT is poor. It was improved by microbial fermentation in a previous study, but whether it affects hypolipidemic activity is unknown. Therefore, we compared the hypolipidemic activity of BT and microbially fermented black tea (EFT). The results demonstrated that BT inhibited weight gain and improved lipid and total bile acid (TBA) levels, and microbial fermentation reinforced this activity. Mechanistically, both BT and EFT mediate bile acid circulation to relieve hyperlipidemia. In addition, BT and EFT improve dyslipidemia by modifying the gut microbiota. Specifically, the increase in Lactobacillus johnsonii by BT, and the increase in Mucispirillum and Colidextribacter by EFT may also be potential causes for alleviation of hyperlipidemia. In summary, we demonstrated that microbial fermentation strengthened the hypolipidemic activity of BT and increased the added value of BT.


Subject(s)
Camellia sinensis , Hyperlipidemias , Humans , Tea , Hyperlipidemias/drug therapy , Hyperlipidemias/prevention & control , Fermentation , Bile Acids and Salts
2.
Altern Ther Health Med ; 30(2): 84-89, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37856800

ABSTRACT

Objective: Many randomized controlled trials (RCTs) have reported the effect of probiotics on reducing plasma lipids with inconsistent results. An explicit systematic review and meta-analysis were conducted in this study to evaluate the effect of probiotics on the lipid profile of healthy and hyperlipidemia participants. Methods: A comprehensive literature search of RCTs was conducted using PubMed, Embase, World Health Organization (WHO) Global Index Medicus, WHO clinical trial registry, and Clinicaltrials.gov. Inclusion criteria included RCTs comparing the use of any strain of a specified probiotic with the placebo control group. The change in lipid profiles was analyzed. Results: The probiotics can decrease the total cholesterol (TC) level in hyperlipidemia participants but not healthy persons (MD = -0.43, 95% CI -0.60 - -0.25, P < .01; MD = -0.09, 95% CI -0.26 - 0.08, P > .05). Probiotics did not reduce high-density lipoprotein cholesterol (HDL-C) in patients with hyperlipidemia or healthy people (MD = -0.01, 95% CI -0.09 - 0.07, P > .05; MD = 0.02, 95% CI -0.04 - 0.09, P > .05). Furthermore, probiotics can reduce the low-density lipoprotein cholesterol (LDL-C) level both in hyperlipidemia and healthy persons (MD = -0.34, 95% CI -0.43 - -0.26, P < .01; MD = -0.15, 95% CI -0.28 - -0.02, P < .05). Lastly, the effect of probiotics on reducing triglyceride (TG) levels was significant in hyperlipidemia persons but not in the healthy population (MD = -0.20, 95% CI -0.37 - -0.04, P < .01; MD = -0.01, 95% CI -0.02 - 0.04, P > .05). Conclusions: Through our analysis, the effect of probiotics on lowering plasma lipid was more obvious in hyperlipidemia participants than healthy population. However, further studies are required to confirm the findings due to pronounced clinical heterogeneity.


Subject(s)
Hyperlipidemias , Probiotics , Humans , Healthy Volunteers , Cholesterol, LDL , Hyperlipidemias/prevention & control , Probiotics/therapeutic use , Health Status
3.
Nutrients ; 15(16)2023 Aug 18.
Article in English | MEDLINE | ID: mdl-37630819

ABSTRACT

Rice bran, a by-product of rice milling, is abundant in bioactive molecules and is highly recognized for its health-promoting properties, particularly in improving metabolic conditions. Building on this knowledge, we aimed to optimize the extraction conditions to maximize the functional efficacy of rice bran extract (RBE) and further validate its impact on lipid metabolism. We found that the optimized RBE (ORBE) significantly suppressed high-fat diet-induced weight gain, hyperlipidemia, and hepatosteatosis in mouse models. ORBE treatment not only suppressed lipid uptake in vivo, but also reduced lipid accumulation in HepG2 cells. Importantly, we discovered that ORBE administration resulted in activation of AMPK and inhibition of STAT3, which are both crucial players in lipid metabolism in the liver. Collectively, ORBE potentially offers promise as a dietary intervention strategy against hyperlipidemia and hepatosteatosis. This study underlines the value of optimized extraction conditions in enhancing the functional efficacy of rice bran.


Subject(s)
Hyperlipidemias , Metabolic Diseases , Oryza , Animals , Mice , Hyperlipidemias/drug therapy , Hyperlipidemias/etiology , Hyperlipidemias/prevention & control , Diet, High-Fat/adverse effects , AMP-Activated Protein Kinases , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Lipids
4.
Food Funct ; 14(16): 7489-7505, 2023 Aug 14.
Article in English | MEDLINE | ID: mdl-37498560

ABSTRACT

Hyperlipidemia is the most well-known cause of metabolic complications and tissue toxicity such as liver steatosis, atherosclerosis and obesity. This study aims to evaluate the preventive effect of loquat fruit peel extract (PE) against tyloxapol-induced hyperlipidemia and related tissue lipotoxicity in mice. The in vivo study was conducted on mice injected daily with tyloxapol at 100 mg per kg B.W. and treated simultaneously with the PE at concentrations of 100 and 200 mg kg-1 or fenofibrate for 28 days. Plasma and tissue lipid biochemical analyses were undertaken using enzymatic methods. The antioxidative stress was revealed by measuring the malondialdehyde content and activities of superoxide dismutase and catalase as well as the scavenging activity against lipoperoxyl radicals. The PE significantly prevented oxidative stress and restored lipid metabolism, plasma glucose, body weight, organ relative mass and biomarkers of hepato-nephrotoxicity as well as the histological structure of the liver and kidneys. It contains five major polyphenols, namely, ferulic acid, caffeic acid, neochlorogenic acid, chlorogenic acid and quercetin. According to molecular docking analysis, these compounds and their circulating metabolites could interact with major proteins implicated in lipid metabolism and oxidative stress. Overall, the study suggests that PE could prevent hyperlipidemia and related toxic tissue complications.


Subject(s)
Hyperlipidemias , Polyphenols , Mice , Animals , Polyphenols/chemistry , Hyperlipidemias/drug therapy , Hyperlipidemias/prevention & control , Hyperlipidemias/metabolism , Molecular Docking Simulation , Plant Extracts/chemistry , Liver/metabolism , Oxidative Stress , Antioxidants/pharmacology , Antioxidants/metabolism
5.
J Nutr Biochem ; 117: 109320, 2023 07.
Article in English | MEDLINE | ID: mdl-36948432

ABSTRACT

Black rice displays a series of properties including regulating lipid metabolism and attenuating liver injury. Our study aimed to investigate the effect of Zixiangnuo black rice (ZG), peeled rice (ZPG), rice bran (ZBG) on lipid metabolism, liver inflammation, gut microbiota and metabolite profiles in high-fat/cholesterol (HFCD) diet mice. A total of five treatment groups were fed a normal control diet or a HFCD with or without Highland barley (HB) supplementation for 10 weeks. The results showed that ZBG significantly improved lipid parameters, liver function and injury and blood glucose indexes related to hyperlipidemia compared with HFCD group. ZBG recovered the disorder of gut microbiota by increasing Bacteroidetes/Firmicutes ratio and Lactobacillus abundance, and decreasing Proteobacteria abundance. ZBG enhanced the levels of six short chain fatty acids. Fecal metabolomics analysis showed that the important differential metabolites between ZBG and HFCD group were Deoxycholic acid and Myclobutanil, and metabolic pathways were Arachidonic acid metabolism and ABC transporters. Results suggested that BR or bran were effective dietary candidates to ameliorate hyperlipidemia.


Subject(s)
Gastrointestinal Microbiome , Hyperlipidemias , Oryza , Mice , Animals , Lipid Metabolism , Oryza/metabolism , Cholesterol/metabolism , Obesity/metabolism , Liver/metabolism , Diet, High-Fat/adverse effects , Hyperlipidemias/etiology , Hyperlipidemias/prevention & control , Hyperlipidemias/metabolism , Metabolomics , Oxidative Stress , Mice, Inbred C57BL
6.
Oxid Med Cell Longev ; 2021: 4706410, 2021.
Article in English | MEDLINE | ID: mdl-34745416

ABSTRACT

Loquat (Eriobotrya japonica Lindl.), a subtropical fruit tree native to Asia, is not only known to be nutritive but also beneficial for the treatment of diabetes in the south of China. To expand its development, this study was undertaken concerning the potential therapeutic role of total sesquiterpene glycosides (TSGs) from loquat leaves in insulin resistance (IR), the major causative factor of type 2 diabetes mellitus (T2DM). Male C57BL/6 mice were fed on high-fat diet (HFD) to induce IR and then were given TSG by oral administration at 25 and 100 mg/kg/day, respectively. TSG notably improved metabolic parameters including body weight, serum glucose, and insulin levels and prevented hepatic injury. Moreover, inflammatory response and oxidative stress were found to be remarkably alleviated in IR mice with TSG supplement. Further research in liver of IR mice demonstrated that TSG repaired the signalings of insulin receptor substrate-1 (IRS-1)/glucose transporter member 4 (GLUT4) and AMP-activated protein kinase (AMPK), which improved glucose and lipid metabolism and prevented lipid accumulation in liver. It was also observed that TSG suppressed the expression of transient receptor potential vanilloid 1 (TRPV1), whereas the signaling pathway of sirtuin-6 (SIRT6)/nuclear factor erythroid 2-related factor 2 (Nrf2) was significantly promoted. Based on the results, the current study demonstrated that TSG from loquat leaves potentially ameliorated IR in vivo by enhancing IRS-1/GLUT4 signaling and AMPK activation and modulating TRPV1 and SIRT6/Nrf2 signaling pathways.


Subject(s)
Diet, High-Fat , Eriobotrya/chemistry , Gene Expression Regulation/drug effects , Glycosides/pharmacokinetics , Hyperglycemia/prevention & control , Hyperlipidemias/prevention & control , Insulin Resistance , Animals , Glucose Transporter Type 4/genetics , Glucose Transporter Type 4/metabolism , Hyperglycemia/etiology , Hyperglycemia/metabolism , Hyperglycemia/pathology , Hyperlipidemias/etiology , Hyperlipidemias/metabolism , Hyperlipidemias/pathology , Insulin Receptor Substrate Proteins/genetics , Insulin Receptor Substrate Proteins/metabolism , Male , Mice , Mice, Inbred C57BL , NF-E2-Related Factor 2/genetics , NF-E2-Related Factor 2/metabolism , Plant Extracts/pharmacology , Plant Leaves , Sesquiterpenes/pharmacology , Sirtuins/genetics , Sirtuins/metabolism , TRPV Cation Channels/genetics , TRPV Cation Channels/metabolism
7.
J Oleo Sci ; 70(11): 1551-1563, 2021.
Article in English | MEDLINE | ID: mdl-34732634

ABSTRACT

Rice bran oil (RBO) has been demonstrated to affect complex malfunctioned conditions such as oxidative stress, hyperlipidemia, hyperglycemia, hypertension, inflammation, abnormal cell growth (cancer), ulceration, immune and cognitive modulation. This unique effect of RBO is due to the presence of well-balanced fatty acid composition and several bioactive compounds, γ- oryzanol (cycloartenyl ferulate, 24-methylenecycloartanyl ferulate, campesterol ferulate, and ß-sitosteryl ferulate), vitamin E (tocopherol and tocotrienol), phytosterols (ß-sitosterol, campesterol and stigmasterol) and other nutrients. The RBO composition of bioactive compounds varied geographically, thus the clear-cut mechanisms of action on complex disease cascades are still required. This review article summarized the RBO compositional profiling and compared it with other edible oils. This article also summarized Bangladesh RBO profiling and their proposed mechanism of action as well as the first line of defense in the prevention, management, and control of complex disease conditions. This review indicates how Bangladesh RBO increase their opportunity to be functional food for 21st century's ailment.


Subject(s)
Food Analysis , Functional Food , Rice Bran Oil/analysis , Rice Bran Oil/chemistry , Anti-Inflammatory Agents , Bangladesh , Fatty Acids/analysis , Hyperglycemia/prevention & control , Hyperlipidemias/prevention & control , Hypertension/prevention & control , Oxidative Stress/drug effects , Phenylpropionates/analysis , Phytochemicals/analysis , Phytosterols/analysis , Rice Bran Oil/pharmacology , Vitamin E/analysis
8.
Food Funct ; 12(21): 10484-10499, 2021 Nov 01.
Article in English | MEDLINE | ID: mdl-34555841

ABSTRACT

Hyperlipidemia is manifested by abnormal levels of circulating lipids and may lead to various cardiovascular diseases. Studies have demonstrated that turmeric supplemented in food can effectively prevent hyperlipidemia. The aim of this study is to elucidate the underlying mechanism. 27 male C57BL/6J mice were randomly divided into three groups, which were fed with a standard diet, a high-fat diet and a high-fat diet supplemented with turmeric powder (2.0% w/w), respectively. After eight weeks of feeding, turmeric intervention significantly reduced the plasma TC, TG, and LDL-C levels and the LDL-C/HDL-C ratio of mice compared with high-fat diet fed mice. TMT-based proteomic analysis showed that the expression of 24 proteins in mouse plasma and 76 proteins in mouse liver was significantly altered by turmeric, respectively. Bioinformatics analysis showed that differential proteins in the plasma were mainly involved in complement and coagulation cascades and the cholesterol metabolism pathway. The differential proteins in the liver were mainly involved in arachidonic acid metabolism, steroid hormone biosynthesis and the PPAR signaling pathway. Key differential proteins were successfully validated by western blot analysis. This study is the first to reveal the preventive mechanism of turmeric on hyperlipidemia from proteomics. The results showed that dietary turmeric could prevent hyperlipidemia through regulating the expression of proteins in metabolism pathways.


Subject(s)
Curcuma/metabolism , Hyperlipidemias/prevention & control , Lipids/blood , Liver/drug effects , Liver/metabolism , Proteomics/methods , Animals , Diet, High-Fat , Disease Models, Animal , Evaluation Studies as Topic , Hyperlipidemias/blood , Hyperlipidemias/metabolism , Lipid Metabolism/drug effects , Male , Mice, Inbred C57BL
9.
Article in English | MEDLINE | ID: mdl-34370653

ABSTRACT

BACKGROUND: The incidence and mortality of hyperlipidemia are increasing year by year, showing a younger trend. At present, the treatment of hyperlipidemia is mainly dependent on western medicine, but its side effects on liver and kidney function are common in clinics. Therefore, it is necessary to study the treatment of hyperlipidemia by augmenting effective dietary nutrition supplements. Vitamin B6 (VitB6), as an essential cofactor for enzymes, participates in lipid metabolism. The effects of VitB6 on hyperlipidemia, however, have not been reported until now. AIM: The present study was to investigate the influence of VitB6 on hepatic lipid metabolism in hyperlipidaemia rats induced by a High-Fat Diet (HFD). METHODS: Male Sprague-Dawley rats were kept on HFD for two weeks to establish the hyperlipidemia model. The rats in low-dosage and high-dosage groups were received 2.00 and 3.00 mg/kg/- day of VitB6 for eight weeks, respectively. RESULTS: The results showed that both doses of VitB6 reduced HFD-induced hepatic Low-Density Lipoprotein Cholesterol (LDL-C); decreased blood cholesterol (TC), triglycerides, LDL-C, atherogenic index (AI), Atherogenic Index of Plasma (AIP), apolipoprotein B (ApoB) and ApoB/apolipoprotein A-1(ApoA1) ratio; increased liver High-Density Lipoprotein Cholesterol (HDL-C) and serum ApoA1; reduced hepatic steatosis and triglyceride accumulation, lowered fat storage, and recovered heart/body and brain/body ratio to a normal level. In addition, VitB6 supplementation markedly decreased HMGR level, increased the mRNA abundance of LDLR and CYP7A1, and protein expression of SIRT1, following the downregulation of SREBP-1 and PPARγ protein expression in the liver of hyperlipidemia rats. CONCLUSION: In summary, oral VitB6 supplementation can ameliorate HFD-induced hepatic lipid accumulation and dyslipidemia in SD rats by inhibiting fatty acid and cholesterol synthesis, promoting fatty acid decomposition and cholesterol transport.


Subject(s)
Hyperlipidemias , Animals , Diet, High-Fat/adverse effects , Dietary Supplements , Hyperlipidemias/drug therapy , Hyperlipidemias/etiology , Hyperlipidemias/prevention & control , Hypolipidemic Agents/pharmacology , Hypolipidemic Agents/therapeutic use , Lipid Metabolism , Liver/metabolism , Male , Rats , Rats, Sprague-Dawley , Vitamin B 6/metabolism , Vitamin B 6/pharmacology , Vitamin B 6/therapeutic use
10.
Biomed Pharmacother ; 141: 111908, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34328087

ABSTRACT

The present investigation was an attempt to evaluate the hypoglycemic, lipid-lowering, antioxidant and hepatoprotective effects of cumin (Cuminum cyminum family: Apiaceae) supplementation in high fat (HF) diet fed rats. Male Wistar rats were divided into four groups, such as control, control+ cumin, HF and HF+ cumin. Oral glucose tolerance test, plasma lipids, oxidative stress parameters, antioxidant enzymes activities, and liver dysfunction marker enzyme activities were evaluated. Additionally, histological staining of liver tissue was performed to evaluate the inflammatory cells infiltration, iron deposition and fibrosis. The current investigation demonstrated that 1% (w/w) supplementation of cumin powder significantly reduced HF diet-induced glucose intolerance, epididymal and mesenteric fat wet weights and lipid parameters like triglycerides, total cholesterol and low-density lipoproteins. Oxidative stress-related biomarkers including thiobarbituric acid reactive substances (TBARS), nitric oxide (NO) and advanced oxidation protein product (APOP) were also reduced by cumin supplementation. Moreover, HF-diet increased the activity of hepatic biomarker enzymes such as alanine transaminase (ALT) and alkaline phosphatase (ALP) activities which were significantly reduced by cumin powder supplementation. On the other hand, cumin powder supplementation was able to restore the reduced glutathione level with parallel augmentation of the antioxidant enzymes activities such as superoxide dismutase (SOD) and catalase in liver of HF diet-fed rats. Additionally, histological assessments confirmed that cumin powder supplementation also normalized the fat droplet deposition and inflammatory cells infiltration in the liver of HF diet-fed rats. This study suggests that cumin powder supplementation ameliorates dyslipidemia, oxidative stress and hepatic damage in HF diet-fed rats.


Subject(s)
Cuminum , Hyperlipidemias/prevention & control , Non-alcoholic Fatty Liver Disease/prevention & control , Oxidative Stress/drug effects , Adipose Tissue/drug effects , Adipose Tissue/metabolism , Animals , Antioxidants/pharmacology , Cholesterol/blood , Diet, High-Fat , Dietary Supplements , Lipoproteins, LDL/blood , Liver/enzymology , Liver Function Tests , Male , Powders , Rats , Rats, Wistar , Seeds/chemistry , Triglycerides/blood
11.
Biomed Pharmacother ; 141: 111846, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34225018

ABSTRACT

In this study, untargeted lipidomics based on UPLC-Q/TOF-MS, network pharmacology and atomic force microscopy were used to explore the common biomarkers of hyperlipidemia and coronary heart disease, the therapeutic mechanism of the main components of Salvia miltiorrhiza as well as the action mechanism of key lipids. Firstly, the serum samples of 30 healthy people, 30 patients with coronary heart disease and 30 patients with hyperlipidemia were analyzed by using lipidomics technology to obtain biomarkers which can be used to link hyperlipidemia and coronary heart disease and to find potential targets; then, the key components and core targets of Salvia miltiorrhiza intervention in hyperlipidemia and coronary heart disease were analyzed by network pharmacology, the results were verified by atomic force microscopy. It showed that SMS2 might be the key target. And through network pharmacology and atomic force microscope analysis, it can be inferred that salvianolic acid A can combine with SMS2 to play a therapeutic role.


Subject(s)
Coronary Disease/prevention & control , Hyperlipidemias/prevention & control , Lipidomics , Metabolic Networks and Pathways/drug effects , Network Pharmacology , Salvia miltiorrhiza/chemistry , Caffeic Acids/pharmacology , Chromatography, High Pressure Liquid , Female , Healthy Volunteers , Humans , Lactates/pharmacology , Male , Membrane Proteins/drug effects , Microscopy, Atomic Force , Middle Aged , Nerve Tissue Proteins/drug effects , Transferases (Other Substituted Phosphate Groups)/drug effects
12.
Nutr Res ; 92: 1-11, 2021 08.
Article in English | MEDLINE | ID: mdl-34157593

ABSTRACT

Clinical trials have reported that a four-oil intravenous lipid emulsion (SMOFlipid) play a positive role in immune function, but showed inconsistent outcomes compared to other lipid emulsions. A systematic review and meta-analysis was conducted to evaluate the effect of SMOFlipid on liver function, triglycerides (TG), inflammatory markers, and clinical outcomes in hospitalized adults after short-term use compared to others. A search of the PubMed, Medline, Embase, China National Knowledge Infrastructure, and Wanfang databases was performed to identify the included randomized controlled trials. Trials with adults who were administrated a short-term course of SMOFlipid were included. A meta-analysis on liver function markers, TG, inflammatory markers, and clinical outcomes was conducted. A total of 18 randomized controlled trials with 1188 patients were included. Compared to other lipid emulsions, SMOFlipid was associated with a significant reduction in ALT, AST, γ-glutamyltransferase, total bilirubin, TG, C-reactive protein and length of hospital stay. No effect on serum interleukin-6 levels or adverse events were observed. For adult patients, our meta-analysis indicated that SMOFlipid may be beneficial to the liver and prone to prevent hyperlipidemia. The SMOFlipid also shortened length of hospital stay.


Subject(s)
Fat Emulsions, Intravenous/pharmacology , Fatty Acids, Omega-3/pharmacology , Fish Oils/pharmacology , Length of Stay , Liver/drug effects , Olive Oil/pharmacology , Parenteral Nutrition , Soybean Oil/pharmacology , Triglycerides/blood , Adult , Fat Emulsions, Intravenous/chemistry , Fat Emulsions, Intravenous/metabolism , Fat Emulsions, Intravenous/therapeutic use , Fatty Acids, Omega-3/blood , Fatty Acids, Omega-3/therapeutic use , Fish Oils/blood , Fish Oils/therapeutic use , Humans , Hyperlipidemias/prevention & control , Inflammation/prevention & control , Liver/metabolism , Olive Oil/therapeutic use , Plant Oils/metabolism , Plant Oils/pharmacology , Plant Oils/therapeutic use , Soybean Oil/blood , Soybean Oil/therapeutic use , Triglycerides/pharmacology , Triglycerides/therapeutic use
13.
Article in English | MEDLINE | ID: mdl-34065454

ABSTRACT

In our randomized controlled trial, we investigated whether Wu-style Tai Chi (Tai Chi combined with Daoyin) as a potential exercise prescription is more effective than simplified Tai Chi in the prevention and treatment of hypertension and hyperlipidemia in the middle-aged and elderly. We randomly assigned 66 patients with hypertension and hyperlipidemia to one of the two groups: the Wu-style Tai Chi group or the simplified Tai Chi group; the simplified Tai Chi group only exercised simplified Tai Chi three times a week for 6 weeks. The Wu-style Tai Chi group participated in 60 min of Wu-style Tai Chi three times a week for 6 weeks. Serum biochemical tests were conducted at baseline and at the end of the study. Measurements of blood pressure were performed at the same time. Primary outcomes were compared within and between groups at baseline and at 6 weeks. The participants in the Wu-style Tai Chi group performed, at 6 weeks, significantly better than baseline on all of the primary outcomes (p value ≤ 0.05). The results also show significant difference within the simplified Tai Chi group from baseline to 6 weeks in TCHO (mmol/L), SBP (mmHg), and LDL-C (mmol/L) (p value < 0.05). From baseline to 6 weeks, the Wu-style Tai Chi group had significant differences at more test indexes in serum and blood pressure than the simplified Tai Chi group. At 6 weeks, the Wu-style Tai Chi group had a significantly greater mean improvement in the SBP (mmHg) than did the simplified Tai Chi group (mean between-group difference, -5.80 (mmHg) [95% CI, -14.01 to 2.41]; p = 0.007). The results showed that, compared with simplified Tai Chi, Wu-style Tai Chi had a better effect on hypertension in the middle-aged and elderly. At 6 weeks in LDL-C (mmol/L), the Wu-style Tai Chi group had significantly greater improvement between the two groups (means between-group difference, -0.45 (mmol/L) [95% CI, -0.89 to -0.17]; p = 0.03). The results showed that Wu-style Tai Chi protected the cardiovascular system of the middle-aged and elderly in improving LDL-C (mmol/L), and was more significant than simplified Tai Chi. After 6 weeks of exercise, Wu-style Tai Chi could effectively improve hyperlipidemia and hypertension. The total effective rate of cardiovascular disease was 90.00%. There was significant difference in the treatment effect of hypertension and hyperlipidemia between the two groups during 6 weeks (p = 0.039), showing that, in a small population of middle-aged and elderly subjects, Wu style Tai Chi could be useful in managing important CV risk factors, such as hypertension and hyperlipidemia.


Subject(s)
Cardiovascular Diseases , Hyperlipidemias , Hypertension , Tai Ji , Aged , Blood Pressure , Humans , Hyperlipidemias/prevention & control , Hypertension/prevention & control , Middle Aged
14.
Biosci Rep ; 41(6)2021 06 25.
Article in English | MEDLINE | ID: mdl-34036306

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Gualou Xiebai Banxia (GLXBBX) decoction is a well-known traditional Chinese herbal formula that was first discussed in the Synopsis of the Golden Chamber by Zhang Zhongjing in the Eastern Han Dynasty. In traditional Chinese medicine, GLXBBX is commonly prescribed to treat cardiovascular diseases, such as coronary heart disease and atherosclerosis. OBJECTIVE: The present study aimed to examine GLXBBX's preventative capacity and elucidate the potential molecular mechanism of Poloxamer 407 (P407)-induced hyperlipidemia in rats. MATERIALS AND METHODS: Both the control and model groups received pure water, and the test group also received a GLXBBX decoction. For each administration, 3 ml of the solution was administered orally. To establish hyperlipidemia, a solution mixed with 0.25 g/kg P407 dissolved in 0.9% normal saline was injected slowly into the abdominal cavity. At the end of the study, the rats' plasma lipid levels were calculated using an automatic biochemical analyzer to evaluate the preventative capability of the GLXBBX decoction, and the serum and liver of the rats were collected. RESULTS: The GLXBBX decoction significantly improved P407-induced hyperlipidemia, including increased plasma triglycerides (TGs), aspartate aminotransferase (AST) elevation, and lipid accumulation. Moreover, GLXBBX decoction treatment increased lipoprotein lipase (LPL) activity and mRNA expression of LPL. Furthermore, GLXBBX significantly suppressed the mRNA expression of stearoyl-CoA desaturase (SCD1). CONCLUSION: GLXBBX significantly improved P407-induced hyperlipidemia, which may have been related to enhanced LPL activity, increased LPL mRNA expression, and decreased mRNA expression of SCD1.


Subject(s)
Drugs, Chinese Herbal/pharmacology , Hyperlipidemias/prevention & control , Hypolipidemic Agents/pharmacology , Lipids/blood , Animals , Biomarkers/blood , Disease Models, Animal , Hyperlipidemias/blood , Hyperlipidemias/chemically induced , Lipoprotein Lipase/genetics , Lipoprotein Lipase/metabolism , Male , Poloxamer , Rats, Wistar , Stearoyl-CoA Desaturase/genetics , Stearoyl-CoA Desaturase/metabolism
15.
Mol Nutr Food Res ; 65(14): e2001199, 2021 07.
Article in English | MEDLINE | ID: mdl-34014027

ABSTRACT

SCOPE: Diallyl trisulfide (DATS), an organosulfur compound generates in crushed garlic, has various beneficial health effects. A growing body of evidence indicates that miRNAs are involved in the pathology of lifestyle diseases including obesity. The anti-obesogenic effect of garlic is previously reported; however, the effects of DATS on obesity, and the relationship between garlic compounds and the involvement of miRNA remains unclear. Here, the anti-obesogenic activity of DATS and the potential role of miRNA in a diet-induced obesity rat model are investigated. METHODS AND RESULTS: Oral administration of DATS suppressed body and white adipose tissue (WAT) weight gain in rats fed a high-fat diet compared with vehicle-administered rats. DATS lowered the plasma and liver triglyceride levels in obese rats, and decreased lipogenic mRNA levels including those of Srebp1c, Fasn, and Scd1 in the liver. DATS also suppressed de novo lipogenesis in the liver. Transcriptomic analyses of miRNA and mRNA in the epididymal WAT of obese rats using microarrays revealed that DATS decreased miRNA-335 expression and normalized the obesity-related mRNA transcriptomic signatures in epididymal WAT. CONCLUSION: The potent anti-obesogenic effects of DATS and its possible mechanism of action was clearly demonstrated in this study.


Subject(s)
Adipose Tissue, White/drug effects , Allyl Compounds/pharmacology , MicroRNAs/metabolism , Obesity/prevention & control , Sulfides/pharmacology , Adipose Tissue, White/metabolism , Animals , Diet, High-Fat , Garlic , Hyperlipidemias/prevention & control , Liver/drug effects , Male , Rats , Rats, Sprague-Dawley , Transcriptome , Weight Gain
16.
Eur J Pharmacol ; 902: 174120, 2021 Jul 05.
Article in English | MEDLINE | ID: mdl-33905703

ABSTRACT

Atherosclerosis can cause severe cardiovascular diseases, which is the most common cause of death in the world. It's of great significance to study the prevention and treatment of atherosclerosis. Selenium nanoparticles (SeNPs) has drawn more and more attention due to high biological activity, high bioavailability, strong antioxidant capacity and low toxicity, exhibiting great potential in biomedical application. Thus, this study aimed at explore the anti-atherosclerotic effect of two kinds of SeNPs, bovine serum albumin (BSA) surface-decorated SeNPs and chitosan (CS) surface-decorated SeNPs (CS-SeNPs), in apolipoprotein E deficient (ApoE-/-) mice fed with a high-cholesterol and high-fat diet, and the possible mechanisms. The results demonstrated that both BSA-SeNPs (25, 50 and 100 µg Se/kg body weight/day) and CS-SeNPs (50 µg Se/kg body weight/day) could reduce atherosclerotic lesions in ApoE-/- mice after oral administration for 12 weeks. And these effects might mainly attributed to the ability of BSA-SeNPs and CS-SeNPs to inhibit hyperlipidemia by suppressing hepatic cholesterol and fatty acid metabolism, and alleviate oxidative stress by enhancing antioxidant activity. Moreover, the benefits of BSA-SeNPs were dose-dependent and the medium dose of BSA-SeNPs (50 µg Se/kg body weight/day) was optimal. Generally, BSA-SeNPs with mean size 38.5 nm and negative surface charge showed better anti-atherosclerotic effect than CS-SeNPs with mean size 65.8 nm and positive surface charge. These results suggested that SeNPs could significantly alleviate the formation of atherosclerosis in ApoE-/- mice, possibly by inhibiting hyperlipidemia and oxidative stress, exhibiting a potential to serve as an anti-atherosclerotic agent.


Subject(s)
Atherosclerosis/prevention & control , Hyperlipidemias/prevention & control , Hypolipidemic Agents/chemistry , Hypolipidemic Agents/pharmacology , Nanoparticles/chemistry , Selenium/chemistry , Selenium/pharmacology , Administration, Oral , Alanine Transaminase/blood , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/pathology , Apolipoproteins E/deficiency , Atherosclerosis/chemically induced , Atherosclerosis/genetics , Atherosclerosis/pathology , Body Weight/drug effects , Chitosan/administration & dosage , Chitosan/chemistry , Cholesterol/genetics , Cholesterol/metabolism , Cholesterol/toxicity , Diet, High-Fat/adverse effects , Disease Models, Animal , Fatty Acids/genetics , Fatty Acids/metabolism , Hyperlipidemias/blood , Hyperlipidemias/chemically induced , Hyperlipidemias/genetics , Hypolipidemic Agents/administration & dosage , Male , Mice, Inbred C57BL , Mice, Knockout , Nanoparticles/administration & dosage , Nitric Oxide/blood , Oxidative Stress/drug effects , Selenium/administration & dosage , Selenium/metabolism , Serum Albumin, Bovine/administration & dosage , Serum Albumin, Bovine/chemistry , Sodium Selenite/administration & dosage , Sodium Selenite/chemistry , Sodium Selenite/pharmacology , Tumor Necrosis Factor-alpha/blood
17.
Food Res Int ; 139: 109956, 2021 01.
Article in English | MEDLINE | ID: mdl-33509508

ABSTRACT

Lactobacillus paracasei FZU103, a probiotic previously isolated from the traditional brewing process of Hongqu rice wine, may have the beneficial effect of improving the disorder of lipid metabolism. This study aimed to determine the beneficial effects of L. paracasei FZU103 on improving hepatic lipid accumulation associated with hyperlipidemia. Results indicated that L. paracasei FZU103 intervention significantly inhibited the abnormal growth of body weight and epididymal white adipose tissue (eWAT), prevented the hypertrophy of epididymal adipocytes, ameliorated the biochemical parameters of serum and liver related to lipid metabolism in HFD-fed mice. Histological analysis also showed that the excessive accumulation oflipid dropletsin the livers induced by HFD-feeding was greatly alleviated by L. paracasei FZU103 intervention. In addition, L. paracasei FZU103 also promoted the excretion of bile acids (BAs) through feces. Metagenomic analysis revealed that oral supplementation with L. paracasei FZU103 significantly increased the relative abundance of Ruminococcus, Alistipes, Pseudoflavonifractor and Helicobacter, but decreased the levels of Blautia, Staphylococcos and Tannerella in HFD-fed mice. The relationships between lipid metabolic parameters and intestinal microbial phylotypes were also revealed by correlation heatmap and network. Furthermore, ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)-based liver metabolomics demonstrated that L. paracasei FZU103 had a significant regulatory effect on the metabolic pathways of glycerophospholipid metabolism, fatty acid degradation, fatty acid elongation, unsaturated fatty acids biosynthesis, riboflavin metabolism, glycerolipid metabolism, primary bile acid biosynthesis, arachidonic acid metabolism, etc. Additionally, L. paracasei FZU103 intervention regulated expression of hepatic genes involved in lipid metabolism and bile acid homeostasis, and promoted fecal excretion of intestinal BAs. These findings present new evidence supporting that L. paracasei FZU103 has the potential to improve lipid metabolism, and could be used as a potential functional food for the prevention of hyperlipidemia.


Subject(s)
Gastrointestinal Microbiome , Hyperlipidemias , Lacticaseibacillus paracasei , Animals , Diet, High-Fat , Hyperlipidemias/prevention & control , Lipid Metabolism , Mice
18.
Clin Nutr ; 40(2): 420-427, 2021 02.
Article in English | MEDLINE | ID: mdl-32684486

ABSTRACT

BACKGROUND & AIMS: Postprandial lipaemic response has emerged as a risk factor for cardiovascular disease. Dietary fats such as medium-chain saturated fatty acids (MCSFA) and long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) are known to reduce postprandial lipaemic responses. The combination of the two could potentially have complementary and/or synergistic effects for optimising cardiovascular health. This study aims to investigate the effects of MCSFA (coconut oil) with or without LCn-3PUFA (fish oil) inclusion in the test meal on postprandial blood lipids in healthy adults. METHODS: In a randomised, double-blinded, placebo-controlled, 2 × 2 factorial cross-over study, participants (n = 15) were randomised to receive four standardised isocaloric test meals. Test meals include: placebo [PL, containing no fish oil (0 g EPA & DHA) or coconut oil (0 g MCSFA)], fish oil [FO, 6 g fish oil (3.85 g EPA & DHA), containing no coconut oil (0 g MCSFA)], coconut oil [CO, 18.65 g coconut oil (15 g MCSFA), containing no fish oil (0 g EPA & DHA)] and coconut oil + fish oil [COFO, 18.65 g coconut oil (15 g MCSFA) + 6 g fish oil (3.85 g EPA & DHA)]; all providing a total fat content of 33.5 g. Participants received all four treatments on four separate test days with at least 3 days washout in between. Blood parameters were measured by finger pricks at 7 timepoints between 0 and 300min. The primary outcome of this study was the change in postprandial triglycerides (TG) concentrations with secondary outcomes as total cholesterol, high-density lipoprotein cholesterol and blood glucose concentrations. RESULTS: TG area under the curve (AUC) (mmol/L/min) was significantly lower for FO (383.67, p = 0.0125) and COFO (299.12, p = 0.0186) in comparison to PL (409.17) only. TG incremental area under the curve (iAUC) (mmol/L/min) was significantly lower with COFO (59.67) in comparison to CO (99.86), (p = 0.0480). Compared to PL, the change in absolute TG concentrations (mmol/L) from baseline to post TG peak time (180min) after FO were significantly less at 240min (0.39 vs 0.15), 270min (0.2 vs 0.1), and 300min (0.28 vs 0.06), and after COFO was significantly less at 300min (0.28 vs 0.16) (p < 0.05). No significant differences in postprandial AUC and iAUC for any other blood parameters were reported. CONCLUSIONS: Our study demonstrated that LCn-3PUFA with or without MCSFA but not MCSFA alone are effective in reducing postprandial TG in healthy individuals.


Subject(s)
Dietary Fats/administration & dosage , Fatty Acids, Omega-3/administration & dosage , Hyperlipidemias/prevention & control , Meals/physiology , Postprandial Period/drug effects , Adult , Aged , Blood Glucose/metabolism , Cholesterol/blood , Coconut Oil/administration & dosage , Cross-Over Studies , Double-Blind Method , Female , Fish Oils/administration & dosage , Food, Fortified , Healthy Volunteers , Humans , Hyperlipidemias/etiology , Lipoproteins, HDL/blood , Male , Middle Aged , Triglycerides/blood
19.
Pak J Pharm Sci ; 34(6): 2205-2211, 2021 Nov.
Article in English | MEDLINE | ID: mdl-35034882

ABSTRACT

Plant components have been extensively evaluated for their pharmacological activities. This study provides scientific rationale towards the therapeutic effect of Eucalyptus camaldulensis aqueous bark extract against induced atherosclerosis and hyperlipidemia in pigeons. Phytochemical components of Eucalyptus bark extract possess a great antioxidant activity that potentially reduced the risk of heart diseases. A total of 42 Pigeons of both sexes were distributed into negative control (fed normal grain diet), hyperlipidemic control (fed HFD 1% animal fat oil and 0.1% cholesterol for 3 months), test groups of variable doses (0.05, 0.1, 0.2 to 0.4 gms/kg BW for 21 days) and the group received atorvastatin daily after induction used. At the end of the experiment biochemical and histological evaluation has been performed. After HFD induction the serum levels of liver enzyme AST, glucose, urea, cholesterol, LDL, VLDL, and TG were significantly increased with the reduction in HDL levels. The atherogenic index was also found significantly raised. Microscopic examination of the liver and aorta showed the appearance of lipid-filled foam cells all over the liver parenchyma and intima after the HFD induction. Thus it was concluded that Eucalyptus aqueous bark extract can be effective against atherosclerosis and hyperlipidemia.


Subject(s)
Aortic Diseases/prevention & control , Atherosclerosis/prevention & control , Eucalyptus , Hyperlipidemias/prevention & control , Hypolipidemic Agents/pharmacology , Plant Extracts/pharmacology , Animal Feed , Animals , Aorta/drug effects , Aorta/metabolism , Aorta/pathology , Aortic Diseases/blood , Aortic Diseases/etiology , Aortic Diseases/pathology , Atherosclerosis/blood , Atherosclerosis/etiology , Atherosclerosis/pathology , Biomarkers/blood , Columbidae , Diet, High-Fat , Disease Models, Animal , Eucalyptus/chemistry , Female , Hyperlipidemias/blood , Hyperlipidemias/etiology , Hypolipidemic Agents/isolation & purification , Lipids/blood , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Plant Bark , Plant Extracts/isolation & purification , Plaque, Atherosclerotic
20.
Int Immunopharmacol ; 91: 107173, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33352441

ABSTRACT

Cordycepin (CRD), an adenosine analog derived from traditional Chinese medicine, is an active component in Cordyceps militaris. It has been shown to have many protective effects during liver injury and ameliorate liver disease progression, but little is known about its effect on non-alcoholic fatty liver disease (NAFLD). This study aims to explore the effects of CRD on obesity-induced NAFLD. In this experiment, C57BL/6 J mice were randomly assigned into normal control group (NC), high fat diet group (HFD) and HFD + CRD group for 8 weeks. The body weights were recorded weekly, at the end of the experiments, the liver and serum samples were collected. We found that CRD administration reduced body weight and decreased the weight of adipose and liver, and CRD relieved liver injure through diminishing of histopathological changes and decreasing serum levels of AST, ALT, TG, TC, LDL-C and increased the level of HDL-C. Furthermore, treatment with CRD significantly alleviated expression of inflammatory factors (TNF-α, IL-6 and Il-1ß) and macrophage markers (MCP1, MIP2, mKC and VCAM1). On the other hand, compared with HFD group, the CRD treated group markedly down-regulated relative proteins of lipid anabolism (SREBP1-c, ACC, SCD-1, LXRα and CD36) and up-regulated relative proteins of ß-oxidation (p-AMPK, AMPK, CPT-1 and PPARα). In summary, our results suggest that CRD can be a potential therapeutic agent in the prevention and treatment of NAFLD, which may be closely related to its effect on lipid metabolism and inflammatory responses.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Deoxyadenosines/pharmacology , Hypolipidemic Agents/pharmacology , Inflammation Mediators/metabolism , Lipids/blood , Lipogenesis/drug effects , Liver/drug effects , Non-alcoholic Fatty Liver Disease/prevention & control , Animals , Diet, High-Fat , Disease Models, Animal , Down-Regulation , Hyperlipidemias/immunology , Hyperlipidemias/metabolism , Hyperlipidemias/prevention & control , Liver/immunology , Liver/metabolism , Liver/pathology , Male , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/immunology , Non-alcoholic Fatty Liver Disease/metabolism , Non-alcoholic Fatty Liver Disease/pathology , Obesity/immunology , Obesity/metabolism , Obesity/prevention & control , Oxidation-Reduction
SELECTION OF CITATIONS
SEARCH DETAIL